| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | +)-type amino acid transport protein; amino acid transporter 1; ATR1; B(0; B(0,+)-type amino acid transport protein; CSNU1; D2H; FLJ34681; NBAT; Neutral and basic amino acid transport protein rBAT; RBAT; SLC31_HUMAN; SLC3A1; SLC3A1 variant B; SLC3A1 variant C; SLC3A1 variant D; SLC3A1 variant E; SLC3A1 variant F; SLC3A1 variant G; solute carrier family 3 (cystine; dibasic and neutral amino acid transporters); member 1; Solute carrier family 3 member 1 |
| Clonality | |
| Conjugate | |
| Form | Liquid |
| Host | |
| Immunogen | Recombinant Human Neutral and basic amino acid transport protein rBAT protein (1-68AA) |
| Isotype | |
| Product Type | |
| Reactivity | |
| Source | This product is a polyclonal antibody purified from rabbit antiserum. |
| Storage | |
| Target | |
| UniProt # |
Overview
This polyclonal anti-SLC3A1 antibody raised in Rabbit, conjugated with FITC. Designed to detect SLC3A1 in Human for others research.
Key elements and design rationale
- Immunogen: Recombinant Human Neutral and basic amino acid transport protein rBAT protein (1-68AA) — determines epitope; confirm sample prep compatibility.
- Host (Rabbit): Requires anti-rabbit-IgG secondary matching isotype IgG.
- Polyclonal: Multiple epitopes = robust signal; lot-to-lot variability — include controls.
- Isotype (IgG): Match secondary, Protein A/G, and isotype controls to IgG.
- Purification (Protein G purification): Enriches Ig classes; reduces non-specific background.
- FITC: Direct fluorescence (Ex490/Em525); protect from light; use antifade.
Biological background
SLC3A1 (also: +)-type amino acid transport protein, amino acid transporter 1, ATR1, B(0, B(0,+)-type amino acid transport protein, CSNU1, D2H, FLJ34681, NBAT, Neutral and basic amino acid transport protein rBAT, RBAT, SLC31_HUMAN, SLC3A1, SLC3A1 variant B, SLC3A1 variant C, SLC3A1 variant D, SLC3A1 variant E, SLC3A1 variant F, SLC3A1 variant G, solute carrier family 3 (cystine, dibasic and neutral amino acid transporters), member 1, Solute carrier family 3 member 1) — studied in Human systems. Expression, localization, and PTMs vary across cell types and disease states. Consult UniProt, NCBI Gene, and primary literature for current SLC3A1 annotation relevant to others.
Common research applications
- Refer to product documentation for confirmed application data.
Notes for experimental interpretation
- Isotype controls: IgG from Rabbit at equivalent concentration.
- Cross-reactivity: Polyclonal: validate with KO/KD controls.
- Matrix effects: Verify dilution linearity in your sample matrix.
- Reactivity: Confirmed for Human; extrapolation requires validation.
This product is a polyclonal antibody purified from rabbit antiserum.
SLC3A1 is a protein studied in Human biology. This polyclonal antibody raised in Rabbit detects SLC3A1 in immunoassay applications, IgG isotype.
Reported reactive against Human. Immunogen from Human. Cross-reactivity with untested species requires empirical confirmation.
Application data not specified. Consult datasheet or contact BioHippo support.
FITC (Ex490/Em525): direct fluorescence; protect from light; use antifade for sections.
(1) Isotype control: IgG from Rabbit; (2) Positive control: lysate/cell line expressing SLC3A1; (3) Negative control: siRNA KD or KO; (4) Dilution linearity in your sample matrix.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
